Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:12:27 EDT Mon 10 Aug 2026
Enter Symbol
or Name
USA
CA



Q:CYTK - CYTOKINETICS INC - https://www.cytokinetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYTK - Q6.876.89·76.951.576.95+0.190.21,088.582,65512,22576.09  77.075  75.6788.31  32.8913:52:59Aug 0615 min RT 2¢

Recent Trades - Last 10 of 12225
Time ETExPriceChangeVolume
13:53:03Q76.9150.1552
13:53:03Q76.92140.16141
13:52:59Q76.940.181
13:52:58Q76.92180.16183
13:52:51Q76.890.1321
13:52:48Q76.9150.15510
13:52:48Q76.910.158
13:52:46Q76.92230.162361
13:52:46Q76.92230.162339
13:52:42Q76.92420.16424

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-06 16:00U:CYTKNews ReleaseCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 06:20U:CYTKNews ReleaseCytokinetics Announces MHRA Marketing Authorisation for MYQORZO(TM)▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
2026-07-23 16:00U:CYTKNews ReleaseCytokinetics to Announce Second Quarter Results on August 6, 2026
2026-07-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07 07:30U:CYTKNews ReleaseCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
2026-06-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-08 07:30U:CYTKNews ReleaseCytokinetics Announces Call for Proposals for Annual Corporate Giving Program
2026-06-01 07:30U:CYTKNews ReleaseCytokinetics Launches MYQORZO(TM) (aficamten) in European Union, with First Commercial Availability in Germany
2026-05-27 16:00U:CYTKNews ReleaseCytokinetics to Participate in June Investor Conferences
2026-05-20 16:00U:CYTKNews ReleaseCytokinetics to Hold Annual Meeting of Stockholders
2026-05-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-14 07:30U:CYTKNews ReleaseCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
2026-05-12 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-11 10:06U:CYTKNews ReleaseCytokinetics Announces New Data Related to MYQORZO(TM) (aficamten) at ESC Heart Failure 2026
2026-05-08 10:52U:CYTKNews ReleaseCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million
2026-05-06 23:00U:CYTKNews ReleaseCytokinetics Announces Pricing of Upsized Public Offering of Common Stock
2026-05-05 16:15U:CYTKNews ReleaseCytokinetics Announces Proposed Public Offering of Common Stock
2026-05-05 16:05U:CYTKNews ReleaseCytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 07:30U:CYTKNews ReleaseCytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
2026-05-04 16:00U:CYTKNews ReleaseCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026